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Purpose: Tranexamic acid (TXA) is a widely used antifibrinolytic agent that can also cause a 
decrease in vascular permeability. We hypothesized that TXA could improve macular edema 
(ME) that is caused by an increase in retinal vascular permeability. The aim of this study is 
to evaluate the efficacy of oral TXA for ME associated with retinal vein occlusion (RVO) or 
diabetic ME (DME).
Patients and methods: Oral TXA (1,500 mg daily for 2 weeks) was administered to patients 
with persistent ME secondary to RVO (7 eyes) and DME (7 eyes). After 2 weeks (ie, the final 
day of administration) and 6 weeks (ie, 4 weeks after the final administration), best-corrected 
visual acuity and central macular thickness (CMT) were measured and compared with baseline. 
Analyses were performed for RVO and DME cases. No other treatment was performed during 
the study period.
Results: In RVO cases, significant improvement in CMT was found between baseline 
(467.7±121.4 µm) and 2-week measurements after treatment (428.7±110.5 µm, p=0.024). 
No significant change was found in CMT between measurements taken at baseline and 6 weeks 
after treatment. In DME cases, no significant change was found in CMT between measurements 
taken at baseline and 2 or 6 weeks after treatment. In all analyses of best-corrected visual acuity, 
no significant change was observed.
Conclusion: The results support the hypothesis that plasmin plays a role in the development of 
ME associated with RVO, and oral TXA administration may be useful as an adjuvant treatment 
when combined with other agents such as anti-vascular endothelial growth factor.
Keywords: diabetic macular edema, fibrin, macular edema, plasmin, retinal vein occlusion, 
tranexamic acid
Introduction
Macular edema (ME) is a major cause of visual impairment in patients with retinal 
vascular disorders, such as retinal vein occlusion (RVO) and diabetic ME (DME).1 
Although the pathogenesis of ME is complex, the most direct mechanism is the 
disruption of the blood–retinal barrier. Because vascular endothelial growth factor 
(VEGF) is believed to play a key role in the disruption of the blood–retinal barrier, 
the use of intravitreal injections of anti-VEGF agents to treat ME has been increasing 
during the last decade.2 Anti-VEGF therapy is regarded as the first-line treatment 
in a majority of ME cases, and numerous studies have demonstrated its efficacy. 
However, there is a risk of severe complications, including infectious endophthalmitis 
and retinal detachment, arising from the use of intravitreal injection, although these 
are relatively rare.3,4 Systemic side effects, including an increase in thromboembolic 
events5,6 and kidney toxicity,7,8 have also been reported. Although ocular side effects 
have not yet been clearly defined, some unfavorable phenomena have been reported, 
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including choroidal thinning, retinal pigment epithelium tear, 
uveitis, retinal venous occlusion, retinal artery occlusion, and 
ocular hypertension.9–11 In addition, prolonged and extreme 
inhibition of VEGF, which is induced by repeated injections, 
may interfere with the physiological function of the retina.12 
Moreover, commercially available anti-VEGF agents are 
expensive and so have important social implications.13 Given 
the concerns surrounding the use of intravitreal injection of 
anti-VEGF agents, alternative treatments and methods to 
decrease the frequency of injection require investigation.
Plasmin, which is converted from plasminogen by 
plasminogen activator, is known as the principal enzyme in 
the fibrinolytic system and is recognized for its many non-
fibrinolytic activities, including the promotion of vascular 
permeability and neuronal injury.14 Previous reports have 
demonstrated that plasmin can disrupt the blood–brain barrier 
and contribute to the development of brain edema.14,15 The 
known pathways through which plasmin promotes vascular 
permeability include the following: activation of matrix 
metalloproteinases, which are the principal regulators of 
vascular permeability;16,17 degradation of vascular basement 
membrane components, including collagen IV, laminin, and 
fibronectin;14,18 activation of platelet-derived growth factor-C 
pathway;14 promotion of an inflammatory response;19–23 
and contraction24,25 or apoptosis26 of vascular endothelial 
cells. Furthermore, plasmin acts on both intravascular and 
extravascular tissues. In the brain, excessive plasmin activity, 
often induced by ischemia, injures neurons.27–29 Taken 
together, plasmin can injure both the vascular structures 
and the whole neurovascular unit. In accordance with the 
concept of a common neurovascular unit between the brain 
and retina, we suspected that plasmin may contribute to the 
development of ME and retinal cell damage secondary to 
retinal vascular disease.
Tranexamic acid (TXA) is a widely used antifibrinolytic 
agent that was discovered in the 1960s.30 It binds to lysine-
binding sites on plasminogen and subsequently causes 
decreased activation of plasminogen to plasmin.31 It has been 
clinically demonstrated to induce hemostasis, reduce inflam-
mation, and decrease vascular permeability. As a hemostatic 
agent, clinical indications for TXA are hyphema, menor-
rhagia, trauma, and perioperative use.31 In addition, TXA has 
been prescribed for the treatment of pharyngitis, laryngitis, 
tonsillitis,32,33 and angioedema34,35 owing to its ability to 
reduce inflammation and vascular permeability.
Given its reported efficacy in the reduction of vascular 
permeability, we hypothesized that TXA could improve 
ME and damaged retinal function associated with retinal 
vascular disease. Because the efficacy, safety, and tolerability 
of TXA were established by previous clinical studies,36,37 we 
administrated oral TXA for the treatment of ME associated 
with RVO or diabetes.
Patients and methods
This study is a prospective, interventional case series of 
14 eyes in 12 patients with ME secondary to RVO (including 
branch RVO [BRVO] and central RVO [CRVO]) and DME. 
The study protocol was approved by the institutional review 
board of Aichi Medical University Hospital, Nagakute, Japan. 
This study was registered at the University Hospital Medical 
Information Network (study ID: UMIN 000014601).
Inclusion criteria were as follows: 1) central macular 
thickness (CMT, average retinal thickness within a 1 mm 
diameter circle centered on the fovea) exceeding 300 µm when 
measured with spectral domain optical coherence tomography 
(RS-3000, Nidek, Aichi, Japan); 2) the presence of chronic 
edema for $6 months; 3) history of persistent ME despite 
previous treatment, including intravitreal injection of an anti-
VEGF agent, sub-Tenon injection of steroid, vitrectomy, or 
laser photocoagulation. Exclusion criteria were as follows: 1) 
optical coherence tomography image showing vitreomacular 
traction or thick epiretinal membrane; 2) inappropriate general 
physical condition, kidney failure (blood creatinine concentra-
tion exceeding 1.5 mg/dL or artificial dialysis), uncontrolled 
hypertension (systolic and diastolic blood pressures exceeding 
160 and 90 mmHg, respectively), or severe hyperglycemia in 
patients with diabetes (glycated hemoglobin values .9.0%); 
3) any treatment for ME within the last 3 months; 4) severe 
impairment in macular function, best-corrected visual acuity 
(BCVA) .1.0 (logarithm of minimum angle of resolution); 
and 5) fluorescein angiogram suggesting involvement of 
aneurysms near the fovea in ME development. All patients 
were informed of the off-label use of TXA, and they provided 
written informed consent for this study.
Before beginning TXA administration, all the patients 
underwent complete ocular examination, including measure-
ment of the BCVA and intraocular pressure, slit-lamp and 
fundus examination, fundus photography, and CMT mea-
surement. TXA (Transamin® capsule, Daiichi Sankyo Co. 
Ltd., Tokyo, Japan) was prescribed for oral administration 
at a dosage of 500 mg thrice daily to achieve a total dosage 
of 1,500 mg per day, for 2 weeks. After 2 weeks (ie, the 
final day of administration) and 6 weeks (ie, 4 weeks after 
the final administration), BCVA and CMT were measured 
and assessed as the main outcomes. No other treatment was 
performed during the study period.
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BCVA and CMT at 2 and 6 weeks were compared with 
those at baseline using one-way analysis of variance. The 
multiplicity of testing was adjusted using Dunnett’s proce-
dure with week 0 as control. Analyses were performed for 
RVO and DME cases because the mechanism for breaching 
the blood–retinal barrier is different in both. All statistical 
tests were 2-sided with a 5% significance level. All analyses 
were performed using the SAS software version 9.4 (SAS 
Institute, Cary, NC, USA).
Results
rVO cases
Seven eyes of 7 patients (6 men and 1 woman) were included. 
The patients’ mean age was 70.1 (range 52–83) years. The 
mean duration of ME was 40.0 (range 11–90) months. Four 
BRVO eyes and 3 CRVO eyes were analyzed together 
as RVO cases. No statistically significant difference was 
found in BCVA between the baseline (0.30±0.17) and the 
2-week (0.32±0.22, p=0.87) and 6-week (0.37±0.23, p=0.58) 
measurements. For CMT, a statistically significant differ-
ence was found between the baseline (467.7±121.4 µm) 
and 2-week (428.7±110.5 µm, p=0.024) measurements. 
However, no significant change was found between the base-
line and 6-week (450.9±128.0 µm, p=0.49) measurements. 
No systemic side effects were found during the study period. 
All RVO patients’ baseline clinical characteristics and results 
are summarized in Table 1. A representative case of BRVO 
is shown in Figure 1.
DMe cases
Seven eyes of 5 patients (all women) were included. The 
patients’ mean age was 63.0 (range 47–74) years. The 
mean duration of ME was 32.3 (range 14–44) months. For 
all 7 DME eyes, no statistically significant difference was 
found in BCVA between the baseline (0.51±0.20) and the 
2-week (0.47±0.16, p=0.71) and 6-week (0.53±0.27, p=0.96) 
measurements. For CMT, no statistically significant differ-
ences were found in the measurements taken at baseline 
(551.3±164.8 µm) compared with those taken at 2 weeks 
(504.9±151.3 µm, p=0.12) and 6 weeks (494.3±152.7 µm, 
p=0.063). No systemic side effects were noted during the 
study period. All DME patients’ baseline clinical character-
istics and results are summarized in Table 2.
Discussion
The current study demonstrated that administration of oral 
TXA could potentially reduce ME associated with RVO. 
Because this was a pilot study, we administered TXA for only T
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2 weeks, and yet we found a significant decrease in CMT 
in RVO cases 2 weeks after the treatment commenced. ME 
rebounded 4 weeks after stopping TXA treatment, suggesting 
that continuous dosing may suppress the edema for a longer 
duration, and the mechanism may not involve morphologi-
cal changes, including remodeling the extracellular matrix. 
There may be several explanations as to why no significant 
decrease in CMT in DME patients was observed. The pres-
ence of ME in DME and RVO could be caused by different 
pathological mechanisms, or the pathological changes may be 
more severe in DME than RVO, and more time is required to 
remedy the condition. Generally, the efficacy of the 2-week 
intake of TXA for ME was limited.
A difference in CMT was found before and after the 
administration of TXA, which suggests that plasmin 
in volvement in ME development associated with RVO is 
similar to that in brain edema. Therefore, plasmin may be 
a therapeutic target for the treatment of ME, although this 
protocol with a 2-week intake of TXA cannot sufficiently 
demonstrate this. In brain capillaries, ischemic injury dam-
ages tight-junction proteins and permits easier access of 
blood-derived plasmin to the basement membrane, creating 
a positive feedback loop.14 Plasmin probably also acts in 
retinal capillaries injured by ischemia. In addition, deposits 
of fibrin have been observed in the retinal capillaries of RVO 
patients.38–40 Fibrin deposits in the retinal capillaries continu-
ously activate plasminogen, and the generated plasmin may 
injure the basement membrane. We speculate that plasmin 
is involved in the development of ME through these mecha-
nisms, and that inhibition of fibrinolytic activity by TXA 
disrupts these mechanisms and decreases ME.
BCVA was unchanged in all analyses, possibly because 
of the latency in visual improvement when compared with 
morphological improvement. Discrepancy between visual 
acuity and CMT is often observed clinically, especially at 
the initial stage of the treatment, where CMT improvement 
occurs earlier and visual improvement is delayed by several 
weeks. Because we administered TXA for only 2 weeks in 
the present study, ME recurred before visual improvement 
was achieved. Longer dosing may lead to an improvement 
in visual acuity.
No side effects of TXA treatment were observed in this 
study. Although the safety of TXA had been established by 
previous clinical studies,36,37 an increased risk of thrombotic 
events should be discussed because patients with retinal 
vascular disease have increased risk of thrombosis.41 Many 
researchers have previously investigated whether TXA 
increases the risk of thrombosis, but came up with con-
flicting results.36,42,43 In a randomized controlled trial that 
included about 20,000 patients with traumatic hemorrhage, 
TXA appeared to decrease the risk of arterial thrombosis.44 
This could be because of the anti-inflammatory properties 
of TXA.45 Therefore, the likelihood of TXA inducing a 
thrombotic event is considered to be low, despite its robust 
antifibrinolytic effect.
Previous studies have shown the associations of various 
types of ME, including retinal swelling, cystoid ME, and 
serous retinal detachment, with the treatment effect. For 
example, ME with serous retinal detachment is known to be 
relatively incurable with anti-VEGF agents.46–48 Although the 
results of our study did not suggest such a tendency, larger 
studies may reveal differences among these types of ME.
Our results showed that the effect of TXA on DME was 
not significant, unlike the effect on RVO. However, whether 
TXA is effective for DME cannot actually be determined. 
The grade of retinal ischemia observed on the fluorescein 
angiogram in all patients with RVO was mild (no patient 
had involvement of more than 5 optic disc areas). In contrast, 
patients with DME exhibited various grades of diabetic retin-
opathy. Although a comparison between RVO and DME is 
%DVHOLQH ZHHNV ZHHNV
&07%&9$ &07%&9$
6XUIDFH,/0 6XUIDFH,/0 6XUIDFH,/0
&07%&9$
Figure 1 Optical coherence tomography scans in a case of branch retinal vein occlusion (eye 2).
Note: The scans demonstrate decreased macular edema after 2-week administration of tranexamic acid and the deterioration at the 6-week time point.
Abbreviations: BCVa, best-corrected visual acuity; CMT, central macular thickness (µm); ilM, internal limiting membrane; logMar, logarithm of minimum angle of resolution.
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not possible, the degree of ischemia in the whole retina of 
patients with DME was generally more severe than that of 
those with RVO. Although we excluded patients with isch-
emic maculopathy, peripheral retinal ischemia can influence 
ME.49 In addition, the baseline CMT in patients with DME 
was considerably severe. These patient characteristics might 
have affected the outcome.
The major shortcomings of this pilot study are the small 
number of participants, heterogeneity among the participants, 
and the lack of a control group. A study with a larger number 
of participants or more rigidly designed criteria is needed.
Conclusion
The results of this pilot study suggest that plasmin plays a role in 
the development of ME associated with RVO and oral admin-
istration of TXA could be a useful adjuvant treatment when 
combined with other treatments such as anti-VEGF agents.
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